Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Days Inventory is 155.34 as of Dec. 2025, which is 18% below its 10-year median of 190.08. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Labiana Health ranks better than 59.37% on this metric.
The historical rank and industry rank for Labiana Health's Days Inventory or its related term are showing as below:
XMAD:LAB'
s Days Inventory Range Over the Past 10 Years
Min: 137.52 Med: 190.08 Max: 240.93
Current: 143.09
During the past 6 years, Labiana Health's highest Days Inventory was 240.93. The lowest was 137.52. And the median was 190.08.
XMAD:LAB's Days Inventory is ranked better than 59.37% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs XMAD:LAB: 143.09
Labiana Health's Days Inventory
increased
from Dec. 2024 (151.04) to Dec. 2025 (155.34).
It might indicate that Labiana Health's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Labiana Health's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.17.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Labiana Health's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.34.
Labiana Health (XMAD:LAB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Labiana Health's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Labiana Health's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Labiana Health Days Inventory Related Terms
Labiana Health Days Inventory Historical Data
* Premium members only.
The historical data trend for Labiana Health's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Days Inventory distribution charts can be found below:
* The bar in red indicates where Labiana Health's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Days Inventory of 155.34 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Labiana Health and its competitors. This is 18% below median its historical median of 190.08. Over the past decade, Labiana Health's Days Inventory has ranged from 137.52 to 240.93. According to the industry distribution chart, Labiana Health ranks #375 out of 923 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Labiana Health's Days Inventory too high?
Labiana Health's current Days Inventory of 155.34 is 18% below median its 10-year median of 190.08. Over the past 10 years, this metric has ranged from a low of 137.52 to a high of 240.93. The Drug Manufacturers industry median Days Inventory is 164.48. Labiana Health's value of 155.34 is 5.6% below this industry median. Based on the distribution chart, Labiana Health ranks #375 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #375 out of 923 companies for Days Inventory. This puts Labiana Health in the upper half of its industry. The industry median Days Inventory is 164.48. Labiana Health's value of 155.34 is 5.6% below this benchmark. Historically, Labiana Health's own Days Inventory has ranged from 137.52 to 240.93 over the past decade. While the company's 10-year median is 190.08 vs. the industry median of 164.48, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Days Inventory of 155.34 is 5.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Days Inventory is 155.34, which is 18% below median its own 10-year median of 190.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current Days Inventory is 155.34, which is 18% below median its 10-year median of 190.08 and 5.6% below the Drug Manufacturers industry median of 164.48. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Days Inventory is 155.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Days Inventory: 155.34 (18% below median its 10-year median of 190.08)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 5.6% below the Drug Manufacturers median (#375 of 923)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
